they need less than half of patients planned in the trial to reach the p needed for FDA.approval.
Maybe they want see if there aren't side effects in multiple doses.
They and the institutionals already know the results.
"Today Merck's Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped early...The trial will be stopped early based on the recommendation of the study's independent Data Monitoring Committee. "
Could the same happen for MAST in Epic trial with MST188?
I think that it is very likely.
do you see BK risk here? Explain, please.
Mast hasn't debts and has a lot of cash, enough to finish all trials.
Stash you are completely wrong , Mast is bargain under 1 dollar, institutionals know this and have been buying and adding since half 2014 , sign of strong confidence.
Sentiment: Strong Buy
there is only one important thing here, now: the P3 with mst188. It is pivotal for this company and it's a remake and an improvement of a previous trial in a sub-set of patient that already showed good and statistical results .
I think that it will be very easy to reach the approval.
Its pipeline ( 1 late P3 and 2-3 P2 ) can be buyed for $0.20 a share.
P3 is an improved sub-set of a previous P3 that shoved to reach statistical significant in this sub-set.
"GlycoMimetics sickle cell VOC candidate reduces time to resolution in study but fails to achieve statistical significance"
this could be a reason of up 15% in 2 days